GSK to buy US cancer treatment firm Nuvalent for $10.6bn
Overview
British drugmaker’s new chief executive Luke Miels announces one of its biggest deals
GSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications.
Details
The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based company that develops cancer drugs, including three for lung cancer.
Continue reading...Source
Originally published at www.theguardian.com.